1-3 of 3
Marc Pelletier
Close
Sort by
Journal Articles

Safety and Preliminary Efficacy of DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study

Guillermo Garcia-Manero, Melissa Ooi, Zhentang Lao, Harinder Gill, Yasmin Abaza, Maximilian Stahl, Tamanna Haque, Amy E. DeZern, Peter L. Greenberg, Marc Pelletier, Arti Singh, Daniel Carreon, Valerie Beaulieu, Janghee Woo
Journal: Blood
Blood (2023) 142 (Supplement 1): 3250.
https://doi.org/10.1182/blood-2023-174642
Published: 2023
Journal Articles

Single-Cell Characterization of the Immune and Leukemic Cells Following Anti-TIM3 and Hypomethylating Agent Combination Therapy in Patients with AML or MDS

Jani Huuhtanen, Oscar Brück, Karita Peltonen, Anna Kreutzman, Olli Dufva, Matti Kankainen, Mette Ilander, Hanna Lähteenmäki, Tiina Kasanen, Jay Klievink, Mika Kontro, Elena J Orlando, Viviana Cremasco, Joel Wagner, Marc Pelletier, Harri Lähdesmäki, Catherine A. Sabatos-Peyton, Mikael L. Rinne, Kimmo Porkka, Satu Mustjoki
Journal: Blood
Blood (2021) 138 (Supplement 1): 801.
https://doi.org/10.1182/blood-2021-147150
Published: 2021
Journal Articles

Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients (Pts) with Very High/High-Risk Myelodysplastic Syndrome (vHR/HR-MDS) and Acute Myeloid Leukemia (AML): Final Analysis from a Phase Ib Study

Andrew M. Brunner, Jordi Esteve, Kimmo Porkka, Steve Knapper, Elie Traer, Sebastian Scholl, Guillermo Garcia-Manero, Norbert Vey, Martin Wermke, Jeroen Janssen, Rupa Narayan, Sun Loo, Mika Kontro, Oliver Ottmann, Purushotham Naidu, Marc Pelletier, May Han, Andrew Lewandowski, Na Zhang, Anisa Mohammed, Mikael L. Rinne, Uma Borate, Andrew H. Wei, Natalia Tovar
Journal: Blood
Blood (2021) 138 (Supplement 1): 244.
https://doi.org/10.1182/blood-2021-146039
Published: 2021